<DOC>
	<DOCNO>NCT02419027</DOCNO>
	<brief_summary>A Multi-center , Randomized , Double-blinded , Placebo-controlled Human Study Evaluate Efficacy Safety probiotic mixture ( ®GI Flora ) Subjects Irritable Bowel Syndrome . Regimen : 6 probiotic mixture &gt; 10^9/D 8 week Primary variable : visual analogue scale ( VAS ) assessment abdominal pain Secondary variable : 1. change VAS score abdominal pain/discomfort 4/8-week treatment 2. daily symptom score bloating , defecation discomfort ( strain/urgency/incomplete evacuation ) , flatulence , feces shape , frequency bowel movement</brief_summary>
	<brief_title>A Multi-center Human Study Evaluate Efficacy Safety ®GI Flora Subjects With Irritable Bowel Syndrome</brief_title>
	<detailed_description />
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Irritable Bowel Syndrome</mesh_term>
	<criteria>Irritable bowel syndrome patient accord Rome III criterion Recurrent abdominal pain discomfort least 3 day per month last 3 month associate least 2 follow characteristic : ) improvement defecation ; b ) onset associate change frequency stool ; c ) onset associate change form ( appearance ) stool . Intolerable hypersensitive GI Flora . Patients active colon diverticulitis . History GI surgeries except hernia repair , appendectomy , primary closure due perforation . History inflammatory bowel disease , malignancy require surgery chemotherapy radiation within 5 year . Patient condition , opinion Investigator , would compromise wellbeing patient requirement study .</criteria>
	<gender>All</gender>
	<minimum_age>19 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>April 2015</verification_date>
	<keyword>GI Flora</keyword>
</DOC>